Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

100%

6 of 6 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 3

2(28.6%)

Phase 1

1(14.3%)

7Total

Phase 2(4)

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01926626Phase 2Completed

Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers

Role: collaborator

NCT01359709Phase 1Completed

Effects of Contingency Management and Nicotine Replacement Therapy on Youth Smoking

Role: collaborator

NCT01806779Phase 2Completed

Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers

Role: collaborator

NCT01560507Phase 2Terminated

Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

Role: collaborator

NCT01303861Phase 3Completed

Concurrent Bupropion / Varenicline for Smoking Cessation

Role: collaborator

NCT01443858Phase 2Completed

Meclizine as a Potential Smoking Cessation Treatment

Role: collaborator

NCT00894166Phase 3Completed

Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype

Role: collaborator

All 7 trials loaded